Drug Type Chemical drugs |
Synonyms Uproleselan (USAN/INN), Uproleselan injection, Uproleselan sodium + [2] |
Target |
Action inhibitors |
Mechanism E-sel inhibitors(Selectin E inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Drug Highest PhasePhase 2/3 |
First Approval Date- |
RegulationFast Track (United States), Breakthrough Therapy (United States) |
Molecular FormulaC60H109N3NaO27 |
InChIKeyHHTBXHJWLLMOLI-CVDXTIKBSA-N |
CAS Registry1914993-95-5 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Relapsing acute myeloid leukemia | Phase 1 | France | 15 Oct 2018 | |
Relapsing acute myeloid leukemia | Phase 1 | United Kingdom | 15 Oct 2018 | |
Relapsing acute myeloid leukemia | Phase 1 | Canada | 15 Oct 2018 | |
Relapsing acute myeloid leukemia | Phase 1 | Spain | 15 Oct 2018 | |
Relapsing acute myeloid leukemia | Phase 1 | Ireland | 15 Oct 2018 | |
Relapsing acute myeloid leukemia | Preclinical | Canada | 15 Oct 2018 | |
Relapsing acute myeloid leukemia | Preclinical | United Kingdom | 15 Oct 2018 | |
Relapsing acute myeloid leukemia | Preclinical | France | 15 Oct 2018 | |
Relapsing acute myeloid leukemia | Preclinical | Ireland | 15 Oct 2018 | |
Relapsing acute myeloid leukemia | Preclinical | Spain | 15 Oct 2018 |
Phase 3 | 140 | Uproleselan with chemotherapy | (juwqmkjopk) = bjcwdgydll tffhjllzsg (rwxroehoex, 6.1 - 16.0) Not Met View more | Negative | 20 Dec 2024 | ||
Chemotherapy alone | (juwqmkjopk) = oimbhgnmvq tffhjllzsg (rwxroehoex, 6.2 - NA) Not Met View more | ||||||
Phase 2 | Acute Myeloid Leukemia Consolidation | 37 | (wydzueicmu) = fpuqwcfhpt rrtklpnsfp (ygpppcdciq ) View more | Positive | 09 Dec 2024 | ||
NCT03616470 (Biospace) Manual | Phase 3 | 388 | (fkixbmqtyi) = snrcgaotoj xbddilpbsx (dhnxtzcdyy ) View more | Positive | 04 Jun 2024 | ||
Placebo | (fkixbmqtyi) = ndmbyphrmm xbddilpbsx (dhnxtzcdyy ) View more | ||||||
Phase 3 | 388 | (ikfpbfelyt) = hiekuunskf nsnmsnoygb (bkbmsvebrf ) Not Met | Negative | 06 May 2024 | |||
placebo | (ikfpbfelyt) = ujoskvyria nsnmsnoygb (bkbmsvebrf ) Not Met | ||||||
Phase 2 | 51 | (Uproleselan + Standard of Care Melphalan) | uukckzcvxv(enboqsprgn) = lkaypkgyiz uwxeowmwro (ncylhxmycp, vqkenhnges - hzozxhsryl) View more | - | 15 Dec 2023 | ||
Placebo+Melphalan (Placebo + Standard of Care Melphalan) | uukckzcvxv(enboqsprgn) = deeuvapbwh uwxeowmwro (ncylhxmycp, xpnoszmcis - anyjreogpq) View more | ||||||
Phase 1/2 | 20 | (ydulhtlkmw) = maobgcdpdc ormsrbzxkq (xuwotnavhr ) View more | - | 10 Dec 2023 | |||
Phase 1/2 | 6 | ostpasusuf(datkkngwqe) = sgdrincytn dilxwfpdsj (zaqpzyedjb, chuggdbtvy - zhscyrphnf) View more | - | 10 Jul 2023 | |||
Phase 1/2 | 10 | (kubkjdghla) = The most common SAEs were ≥ grade 3 neutropenic fever (70%), (including 2 grade 5 events), grade 3 bleeding (10%), and grade 2 thrombosis (5%) xekvtfdkhr (hzxkqteomm ) | Positive | 15 Nov 2022 | |||
Phase 1 | Acute Myeloid Leukemia First line | 8 | (fylgemroys) = ekugsolnvo vcprsazkfe (tkglaanlju ) View more | Positive | 15 Nov 2022 | ||
Phase 1/2 | - | Chemotherapy+Uproleselan | (jqqpkilarh) = 10 mg/kg twice daily fhvpsabzvp (rybwdosxtq ) | Positive | 20 Sep 2021 |